Analyst Rating: Will FibroGen Inc (FGEN) Stock Do Better Than the Market?

Wednesday, November 10, 2021 10:36 AM | InvestorsObserver Analysts

Mentioned in this article

Wall Street is neutral on FibroGen Inc (FGEN). On average, analysts give FibroGen Inc a Buy rating. The average price target is $24.333, which means analysts expect the stock to add by 88.63% over the next twelve months. That average ranking earns FibroGen Inc an Analyst Rating of 12, which is better than 12% of stocks based on data compiled by InvestorsObserver.

Wall Street analysts are rating FGEN a Buy today. Find out what this means to you and get the rest of the rankings on FGEN!
See Full FGEN Report

Why are Analyst Ratings Important?

A company's financial statements are a significant factor weighted by experts when analyzing a company's health. Beyond just the numbers, analysts follow specific industries closely and are able to gain a detailed understanding of how a storm in one part of the world can shutdown supply chains leading to a change in consumption across the globe. This knowledge allows investors to respond to potential changes in the market before they are revealed in a quarterly annoucement. InvestorsObserver averages the ratings across all these analysts and percentile ranks those averages. This allows you to compare stocks in greater detail than the usual five-tiered system used amongst the majority of investors.

What's Happening With FibroGen Inc Stock Today?

FibroGen Inc (FGEN) stock is up 6.75% while the S&P 500 has fallen -0.09% as of 10:35 AM on Wednesday, Nov 10. FGEN has gained $0.87 from the previous closing price of $12.08 on volume of 299,270 shares. Over the past year the S&P 500 is up 32.02% while FGEN has fallen -68.41%. FGEN lost -$2.53 per share the over the last 12 months. Click Here to get the full Stock Report for FibroGen Inc stock.

Share this article:

Related Articles